WO2000058506A3 - Susceptibility to psoriasis - Google Patents

Susceptibility to psoriasis Download PDF

Info

Publication number
WO2000058506A3
WO2000058506A3 PCT/GB2000/001152 GB0001152W WO0058506A3 WO 2000058506 A3 WO2000058506 A3 WO 2000058506A3 GB 0001152 W GB0001152 W GB 0001152W WO 0058506 A3 WO0058506 A3 WO 0058506A3
Authority
WO
WIPO (PCT)
Prior art keywords
psoriasis
susceptibility
medicaments
methods
present
Prior art date
Application number
PCT/GB2000/001152
Other languages
French (fr)
Other versions
WO2000058506A2 (en
Inventor
Richard Charles Trembath
Jonathan Nicholas Willi Barker
Original Assignee
Univ Leicester
King S College London
Richard Charles Trembath
Jonathan Nicholas Willi Barker
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leicester, King S College London, Richard Charles Trembath, Jonathan Nicholas Willi Barker filed Critical Univ Leicester
Priority to EP00912820A priority Critical patent/EP1144678A2/en
Priority to CA002329261A priority patent/CA2329261A1/en
Priority to AU34462/00A priority patent/AU3446200A/en
Priority to JP2000608784A priority patent/JP2002539844A/en
Publication of WO2000058506A2 publication Critical patent/WO2000058506A2/en
Publication of WO2000058506A3 publication Critical patent/WO2000058506A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6881—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/205—Scaling palpular diseases, e.g. psoriasis, pytiriasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention concerns diagnostic tests for susceptibility to psoriasis, together with medicaments and methods for treating same.
PCT/GB2000/001152 1999-03-26 2000-03-27 Susceptibility to psoriasis WO2000058506A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP00912820A EP1144678A2 (en) 1999-03-26 2000-03-27 Susceptibility to psoriasis
CA002329261A CA2329261A1 (en) 1999-03-26 2000-03-27 Susceptibility to psoriasis
AU34462/00A AU3446200A (en) 1999-03-26 2000-03-27 Susceptibility to psoriasis
JP2000608784A JP2002539844A (en) 1999-03-26 2000-03-27 Susceptibility to psoriasis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9906993.2A GB9906993D0 (en) 1999-03-26 1999-03-26 Psoriasis
GB9906993.2 1999-03-26

Publications (2)

Publication Number Publication Date
WO2000058506A2 WO2000058506A2 (en) 2000-10-05
WO2000058506A3 true WO2000058506A3 (en) 2001-08-16

Family

ID=10850413

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/001152 WO2000058506A2 (en) 1999-03-26 2000-03-27 Susceptibility to psoriasis

Country Status (6)

Country Link
EP (1) EP1144678A2 (en)
JP (1) JP2002539844A (en)
AU (1) AU3446200A (en)
CA (1) CA2329261A1 (en)
GB (1) GB9906993D0 (en)
WO (1) WO2000058506A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1731201A (en) * 1999-12-06 2001-06-18 Hidetoshi Inoko Method of examining vulgar psoriasis
GB0004312D0 (en) * 2000-02-23 2000-04-12 Oxagen Limited Test and model for inflammatory disease
AU2085502A (en) * 2000-11-30 2002-06-11 Molecular Skincare Ltd Diagnosis and treatment of disease
FR2853910B1 (en) * 2003-04-16 2007-08-24 Galderma Res & Dev GENES OF PSORIASIS

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2761363A1 (en) * 1997-03-28 1998-10-02 Oreal PURIFYING SKIN POLYPEPTIDE AND ITS USE
FR2761362A1 (en) * 1997-03-28 1998-10-02 Oreal New polypeptide, corneodesmosin, and related nucleic acid

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2761363A1 (en) * 1997-03-28 1998-10-02 Oreal PURIFYING SKIN POLYPEPTIDE AND ITS USE
FR2761362A1 (en) * 1997-03-28 1998-10-02 Oreal New polypeptide, corneodesmosin, and related nucleic acid

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GUERRIN M ET AL: "Expression cloning of human corneodesmosin proves its identity with the product of the S gene and allows improved characterization of its processing during keratinocyte differentiation", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 35, August 1998 (1998-08-01), pages 22640 - 647, XP002160632 *
ISHIHARA M ET AL: "Genetic polymorphisms in the keratin-like S gene within the human major histocompatibility complex and association analysis on the susceptibility to psoriasis vulgaris", TISSUE ANTIGENS, vol. 48, 1996, pages 182 - 86, XP000982321 *
See also references of EP1144678A2 *
TAZI A ET AL: "Novel genetic association between corneodesmosin (MHC S) gene and susceptibility to psoriasis", HUMAN MOLECULAR GENETICS, vol. 8, no. 6, June 1999 (1999-06-01), pages 1135 - 40, XP002160633 *
ZHOU Y ET AL: "IDENTIFICATION IN THE HLA CLASS I REGION OF A GENE EXPRESSED LATE IN KERATINOCYTE DIFFERENTIATION", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,US,NATIONAL ACADEMY OF SCIENCE. WASHINGTON, vol. 90, 1 October 1993 (1993-10-01), pages 9470 - 9474, XP002049396, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
CA2329261A1 (en) 2000-10-05
JP2002539844A (en) 2002-11-26
EP1144678A2 (en) 2001-10-17
AU3446200A (en) 2000-10-16
WO2000058506A2 (en) 2000-10-05
GB9906993D0 (en) 1999-05-19

Similar Documents

Publication Publication Date Title
EP0665590A3 (en) Microstructure, process for manufacturing thereof and devices incorporating the same.
AU5270600A (en) The maize rs324 promoter and methods for use thereof
ZA200201806B (en) Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and the use thereof.
AU4850400A (en) The maize rs81 promoter and methods for use thereof
IL146105A0 (en) 5-pyridyl-1, 3-azole compounds, process for producing the same and use thereof
IL133531A0 (en) 4-haloalkyl-3-heterocyclylpyridines and 4-haloalkyl-5-heterocyclylpyridines, method for the production thereof, agents containing the same and their use as pesticides
HK1018780A1 (en) 6-Phenylpyridine-2-ylamine derivatives, the composition and use thereof.
ZA993364B (en) Novel 4-phenylpiperidines for the treatment of pruritic dermatoses.
MXPA01009437A (en) Elastic polyurethane-urea fiber and process for producing the same.
HK1009814A1 (en) Five-membered heterocycles having biphenylsulfonylsubstitution, process for their prparation, their use as a medicament or diagnostic, and medicament .
DE69818557D1 (en) Anti-rot composition, process for its preparation and product treated with it
ID26612A (en) SICLOBUTENA DECLARATIONS, THEIR PRODUCTION AND THE USE OF THERAPY
AU1974100A (en) 4-trifluoromethyl-3-oxadiazolyl pyridines, methods for the production thereof, agents containing these compounds, and their use as pesticides
HK1041827A1 (en) Compounds for the treatment of estrogen-defendent illnesses and methods for making and using the dame.
PL371784A1 (en) Pentafluorosulfanyl-benzoylguanidine, method for the production thereof and its utilization as medicament or diagnostic agent and medicament containing same
PL351616A1 (en) Polyolefin compositions, method for the production and use thereof
AU9019198A (en) Methods for treating physiological conditions associated with the use, or sequelae of use, of cocaine or other psychomotor stimulants
ZA978640B (en) Use of 1-hydroxy-2-pyridones for the treatment of saborrheic dermatitis.
WO2000058506A3 (en) Susceptibility to psoriasis
AU1138699A (en) Dna demethylase, therapeutic and diagnostic uses thereof
TR199501627A2 (en) Methods and equipment for the production of urea, with different areas of reaction.
ZA9810842B (en) Epoxidation catalyst, its use and epoxidation process in the presence of this catalyst.
ZA200002546B (en) Sorbate-preserved compositions, method for the manufacture thereof and their use.
ZA976735B (en) Substituted indanylidineacetylguanidines, process for their preparation, their use as medicaments or diagnostic and medicaments containing them.
WO2000069841A3 (en) Benzofuranylaminoalcohols

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2329261

Country of ref document: CA

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2000912820

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWP Wipo information: published in national office

Ref document number: 2000912820

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09701257

Country of ref document: US

WWR Wipo information: refused in national office

Ref document number: 2000912820

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000912820

Country of ref document: EP